Compare PTCT & CWAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | CWAN |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 7.1B |
| IPO Year | 2013 | 2021 |
| Metric | PTCT | CWAN |
|---|---|---|
| Price | $75.18 | $24.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 11 |
| Target Price | ★ $73.76 | $30.86 |
| AVG Volume (30 Days) | 1.2M | ★ 13.7M |
| Earning Date | 02-26-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46826.67 |
| EPS | ★ 8.94 | 1.40 |
| Revenue | ★ $1,779,150,000.00 | $640,376,000.00 |
| Revenue This Year | $129.80 | $64.94 |
| Revenue Next Year | N/A | $29.41 |
| P/E Ratio | ★ $8.53 | $17.23 |
| Revenue Growth | ★ 97.54 | 50.91 |
| 52 Week Low | $35.95 | $15.74 |
| 52 Week High | $87.50 | $32.00 |
| Indicator | PTCT | CWAN |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 66.14 |
| Support Level | $73.77 | $24.10 |
| Resistance Level | $77.55 | $24.39 |
| Average True Range (ATR) | 3.50 | 0.09 |
| MACD | -0.10 | -0.13 |
| Stochastic Oscillator | 53.42 | 25.37 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Clearwater Analytics describes its mission as aiming to be the world's most trusted and comprehensive technology platform for the entire investment cycle. Clearwater has historically focused on back-office functions such as investment accounting, but with acquisitions such Enfusion, Beacon, and Bistro, the firm has broadened its focus with front-office and middle-office capabilities. Clearwater primarily serves insurance companies, asset managers, hedge funds, and corporate treasuries. Pro forma for Enfusion, about 76% of Clearwater's revenue is generated in the US.